Resonant Capital Advisors LLC Grows Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Resonant Capital Advisors LLC lifted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 32.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,348 shares of the company’s stock after purchasing an additional 10,082 shares during the period. Resonant Capital Advisors LLC’s holdings in Intellia Therapeutics were worth $1,261,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Barclays PLC increased its stake in shares of Intellia Therapeutics by 15.0% during the third quarter. Barclays PLC now owns 256,626 shares of the company’s stock worth $8,115,000 after purchasing an additional 33,558 shares in the last quarter. ARK Investment Management LLC increased its stake in shares of Intellia Therapeutics by 14.7% during the fourth quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock worth $347,966,000 after purchasing an additional 1,463,820 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Intellia Therapeutics by 5.9% during the third quarter. American Century Companies Inc. now owns 267,213 shares of the company’s stock worth $8,449,000 after purchasing an additional 14,863 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in shares of Intellia Therapeutics by 13.3% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 36,225 shares of the company’s stock worth $1,104,000 after purchasing an additional 4,255 shares in the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of Intellia Therapeutics by 1.4% during the third quarter. Wellington Management Group LLP now owns 2,651,994 shares of the company’s stock worth $83,856,000 after purchasing an additional 36,630 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $21.57 on Friday. The firm has a 50 day simple moving average of $27.21 and a 200-day simple moving average of $27.86. Intellia Therapeutics, Inc. has a 1-year low of $20.78 and a 1-year high of $47.48. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -3.99 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.01. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. The firm had revenue of ($1.92) million for the quarter, compared to analyst estimates of $15.10 million. During the same period in the prior year, the business posted ($1.40) EPS. Equities analysts expect that Intellia Therapeutics, Inc. will post -5.58 earnings per share for the current fiscal year.

Insider Transactions at Intellia Therapeutics

In other news, EVP James Basta sold 2,297 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $32.99, for a total value of $75,778.03. Following the transaction, the executive vice president now directly owns 81,571 shares in the company, valued at approximately $2,691,027.29. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Wedbush reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, February 15th. Canaccord Genuity Group upped their price objective on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Friday, February 23rd. Wolfe Research assumed coverage on shares of Intellia Therapeutics in a research note on Thursday, February 15th. They set a “peer perform” rating for the company. Finally, The Goldman Sachs Group cut shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $136.00 to $32.00 in a research note on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Intellia Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.